Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Non Operating Income data on record, last reported at $362000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income rose 103.19% year-over-year to $362000.0; the TTM value through Dec 2025 reached -$700000.0, up 94.49%, while the annual FY2025 figure was -$700000.0, 42.34% up from the prior year.
  • Non Operating Income reached $362000.0 in Q4 2025 per AMLX's latest filing, up from -$181000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.7 million in Q3 2023 and bottomed at -$11.3 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$410300.0, with a median of -$111000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: surged 18289.47% in 2023, then tumbled 6729.24% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$26000.0 in 2021, then soared by 9592.31% to $2.5 million in 2022, then crashed by 93.07% to $171000.0 in 2023, then crashed by 6729.24% to -$11.3 million in 2024, then skyrocketed by 103.19% to $362000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $362000.0 in Q4 2025, -$181000.0 in Q3 2025, and -$546000.0 in Q2 2025.